Cefoperazone
Cefobid (cefoperazone) is a small molecule pharmaceutical. Cefoperazone was first approved as Cefobid on 1982-11-18. It is used to treat bacterial infections, bacterial pneumonia, bacterial skin diseases, escherichia coli infections, and female genital diseases amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| musculoskeletal diseases | D009140 |
| respiratory tract diseases | D012140 |
| urogenital diseases | D000091642 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| bacterial pneumonia | EFO_1001272 | D018410 | J15.9 |
| bacterial skin diseases | — | D017192 | — |
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| female genital diseases | EFO_0009549 | D005831 | N85 |
| haemophilus infections | EFO_1001127 | D006192 | — |
| infectious bone diseases | — | D001850 | — |
| klebsiella infections | EFO_1001353 | D007710 | — |
| proteus infections | EFO_1001130 | D011512 | — |
| pseudomonas infections | EFO_0001076 | D011552 | — |
Show 6 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0021 | Injection, cefoperazone sodium, 1 gram |
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract infections | D012141 | J06.9 | — | 1 | — | — | — | 1 | |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 1 | 1 |
| Wound infection | D014946 | — | — | — | — | 1 | 1 | ||
| Cholecystitis | D002764 | HP_0001082 | K81 | — | — | — | — | 1 | 1 |
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | — | — | 1 | 1 |
| Abdominal abscess | D018784 | EFO_1001753 | — | — | — | — | 1 | 1 | |
| Risk factors | D012307 | EFO_0003919 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CEFOPERAZONE |
| INN | cefoperazone |
| Description | Cefoperazone is a semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance. It has a role as an antibacterial drug. |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 62893-19-0 |
| RxCUI | 2184 |
| ChEMBL ID | CHEMBL507674 |
| ChEBI ID | 3493 |
| PubChem CID | 44187 |
| DrugBank | DB01329 |
| UNII ID | 7U75I1278D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,525 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more